The Department of Health and Human Services has announced plans to ease restrictions on six unapproved peptides, allowing qualifying compounding pharmacies to prepare the substances while federal regulators consider permanent rule changes.
By yourNEWS Media Newsroom
WASHINGTON — The Trump administration announced Wednesday that it will temporarily ease federal enforcement restrictions on six experimental peptides, allowing certain pharmacies and medical professionals to prepare the substances despite unresolved questions about their safety and effectiveness.
The Department of Health and Human Services outlined the policy in an Oct. 28 notice, saying it would exercise “enforcement discretion” while the Food and Drug Administration considers whether to formally authorize the substances for pharmaceutical compounding.
According to NBC News, the decision advances an initiative supported by HHS Secretary Robert F. Kennedy Jr., who has publicly advocated greater access to peptides used in experimental wellness and medical treatments.
The six substances covered by the policy are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.
They have been promoted for purposes ranging from wound healing and muscle recovery to inflammation reduction, metabolic health and neurological conditions. However, none has received FDA approval establishing its safety and effectiveness for those uses.
Under the proposed policy, the federal government would generally refrain from taking enforcement action against qualifying state-licensed pharmacies, federal facilities and licensed physicians that compound the substances under specified conditions.
The arrangement would permit a regulated prescription-based distribution pathway before the FDA completes its normal rulemaking process.
HHS emphasized that the policy does not constitute drug approval.
“Under President Trump’s leadership, HHS is working to put prevention and patient safety at the center of health care — and that includes confronting the risks of black-market peptides,” department spokesperson Emily Hilliard said in a statement reported by The Washington Post.
“The policy does not grant FDA approval or establish clinical safety and effectiveness. It requires patient-specific prescriptions, traceable ingredients, quality testing, and safety reporting to hold compounders accountable and give patients an alternative to unregulated sellers.”
The administration argues that allowing licensed pharmacies to supply the substances could reduce demand for peptides sold through unregulated online markets, where products are frequently labeled for research use only.
Such products may lack reliable manufacturing controls, potentially exposing consumers to contamination, inaccurate concentrations or ingredients that differ from those advertised.
The temporary policy establishes several conditions for participating compounders, including verified ingredient sourcing, patient-specific prescriptions and reporting of serious adverse events.
Pharmacies would also be required to follow restrictions governing the formulation and administration of individual peptides.
The proposal follows a July meeting of the FDA’s Pharmacy Compounding Advisory Committee, which recommended allowing six of seven peptides under consideration to be used in compounding.
The committee’s recommendations differed from the conclusions of FDA scientific reviewers, who found insufficient evidence supporting the substances’ safety and effectiveness.
According to STAT, the advisory committee’s vote preceded the administration’s decision to pursue a temporary enforcement policy rather than wait for the completion of formal regulatory proceedings.
The disagreement has generated criticism from medical safety advocates who argue that experimental substances should undergo adequate clinical testing before becoming widely available.
Dr. Peter Lurie, a former FDA official who leads the Center for Science in the Public Interest, criticized the approach as effectively “turning a blind eye” to the distribution of drugs that have not been proven effective.
Shabbir Safdar, executive director of the Partnership for Safe Medicines, also raised concerns about the decision.
“Imagine what it means for the nation’s top drug regulator to announce they won’t enforce the laws on people making completely untested compounds and distributing them to the public,” Safdar told NBC News.
Federal regulators previously restricted the compounding of several experimental peptides because of concerns involving insufficient safety information and possible adverse reactions.
In 2023, the FDA identified more than a dozen peptides that raised significant safety concerns when used in compounded drugs.
Some were associated with potential immune reactions, contamination risks or insufficient information about their effects in humans.
The administration’s latest proposal does not eliminate those scientific uncertainties.
Instead, it establishes a temporary regulatory approach while federal officials consider whether the six substances should be added to the list of bulk drug ingredients permitted for compounding under Section 503A of federal law.
Compounding pharmacies prepare medications for individual patients when commercially available products do not adequately meet their medical needs.
Unlike FDA-approved prescription medications, compounded drugs are not individually reviewed by the agency for safety, effectiveness and manufacturing quality before distribution.
Adding new ingredients to the permitted compounding list generally requires a proposed rule, public comment and a final regulatory decision.
The HHS proposal would allow qualifying compounding activity to proceed during that process, subject to the department’s enforcement conditions.
Kennedy has previously criticized restrictions on experimental peptides and said he wants Americans to have greater access to treatments that may support recovery and other health goals.
The substances have attracted growing interest among wellness enthusiasts, athletes and social media influencers, although promotional claims frequently extend beyond the available clinical evidence.
BPC-157 and TB-500 have been marketed for tissue repair and injury recovery, while MOTS-c has attracted attention for possible metabolic effects.
Epitalon has been promoted for sleep and longevity, KPV for inflammation and wound healing, and semax for neurological applications.
Research supporting these proposed uses remains limited, particularly in large, well-controlled human clinical trials.
The new policy is expected to undergo a public comment period as regulators continue working toward a permanent framework.
HHS has indicated that the temporary approach could be reconsidered if new safety problems or product-quality concerns emerge.
For patients, the change could eventually increase access to certain peptides through licensed pharmacies rather than unregulated suppliers. However, access would remain subject to prescription requirements, pharmacy regulations and the limitations imposed by the federal policy.
The administration’s decision represents a change in how federal regulators intend to enforce existing compounding restrictions, not a determination that the six experimental substances are safe or medically effective.
The FDA’s eventual rulemaking process will determine whether the peptides can become permanently eligible for compounding under federal law.
Original article
Comments